Pros and cons of focal therapy for localised prostate cancer
- PMID: 22110990
- PMCID: PMC3200263
- DOI: 10.1155/2011/584784
Pros and cons of focal therapy for localised prostate cancer
Abstract
In prostate cancer, an interesting and intriguing option to overcome the risks of whole-gland treatment is focal therapy, with the aim of eradicating known cancer foci and reducing collateral damages to the structures essential for maintaining normal urinary and sexual function. Ablation of all known lesions would favorably alter the natural history of the cancer without impacting health-related quality of life and allows for safe retreatment with repeated focal therapy or whole-gland approaches if necessary. Our objective is to reassess the possibilities and criticisms of such procedure: the rationale for focal therapy and the enthusiasm come from the success of conservative approaches in treating other malignancies and in the high incidence of overtreatment introduced by prostate cancer screening programs. One of the challenges in applying such an approach to the treatment of prostate cancer is the multifocal nature of the disease and current difficulties in accurate tumor mapmaking.
Similar articles
-
Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.Eur Urol. 2018 Jul;74(1):84-91. doi: 10.1016/j.eururo.2018.01.001. Epub 2018 Jan 17. Eur Urol. 2018. PMID: 29373215
-
New treatments for localized prostate cancer.Urology. 2008 Dec;72(6 Suppl):S36-43. doi: 10.1016/j.urology.2008.08.506. Urology. 2008. PMID: 19095127
-
Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.J Urol. 2021 Jan;205(1):129-136. doi: 10.1097/JU.0000000000001327. Epub 2020 Aug 17. J Urol. 2021. PMID: 33119421
-
Salvage Local Treatments After Focal Therapy for Prostate Cancer.Eur Urol Oncol. 2019 Sep;2(5):526-538. doi: 10.1016/j.euo.2019.03.008. Epub 2019 Apr 15. Eur Urol Oncol. 2019. PMID: 31412013 Review.
-
Targeting the cancer lesion, not the whole prostate.Transl Androl Urol. 2020 Jun;9(3):1518-1525. doi: 10.21037/tau.2019.09.12. Transl Androl Urol. 2020. PMID: 32676439 Free PMC article. Review.
Cited by
-
Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial.Front Oncol. 2023 Apr 6;13:1143716. doi: 10.3389/fonc.2023.1143716. eCollection 2023. Front Oncol. 2023. PMID: 37091187 Free PMC article.
-
Focal laser ablation of prostate cancer: definition, needs, and future.Adv Urol. 2012;2012:589160. doi: 10.1155/2012/589160. Epub 2012 May 16. Adv Urol. 2012. PMID: 22666240 Free PMC article.
-
High intensity focused ultrasound, liver disease and bridging therapy.World J Gastroenterol. 2013 Nov 21;19(43):7494-9. doi: 10.3748/wjg.v19.i43.7494. World J Gastroenterol. 2013. PMID: 24282341 Free PMC article. Review.
-
Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.Nat Rev Urol. 2024 May;21(5):290-302. doi: 10.1038/s41585-023-00834-y. Epub 2023 Dec 19. Nat Rev Urol. 2024. PMID: 38114768 Review.
-
Specimen orientation by marking the peripheral end: (potential) clinical advantages in prostate biopsy.Prostate Cancer. 2011;2011:270403. doi: 10.1155/2011/270403. Epub 2011 Jul 27. Prostate Cancer. 2011. PMID: 22096654 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer Journal for Clinicians. 2008;58(2):71–96. - PubMed
-
- Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU International. 2002;90(2):162–173. - PubMed
-
- Whitmore WF., Jr. Localised prostatic cancer: management and detection issues. The Lancet. 1994;343(8908):1263–1267. - PubMed
-
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized european study. The New England Journal of Medicine. 2009;360(13):1320–1328. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous